Nektar Therapeutics buys back $100 million in convertible debt

By Devika Patel

Knoxville, Tenn., Nov. 6 - Nektar Therapeutics Inc. said it repurchased 32%, or $100 million, of its outstanding convertible debt.

The debt was bought back at a price of approximately 48, for a total purchase price of $47.8 million.

Nektar Therapeutics is a biopharmaceutical company based in San Carlos, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.